drugset / Trial / NCT03878979
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Phase 2
Completed
26 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
Nivolumab, also known as (Bristol Myers Squibb (BMS)) BMS-936558, before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN).
Timeline
- Start
- 2019-07-08
- Primary completion
- 2023-10-17
- Completion
- 2023-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |